← Back to Search

Continuous Infusion of Bupivacaine for Pain Management

Phase 3
Waitlist Available
Led By Tarik Wasfie, MD
Research Sponsored by Ascension Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 days
Awards & highlights

Study Summary

This trial looked at whether using a continuous infusion of local anesthetic for postoperative pain control following laparotomy is more effective than using a local anesthetic infiltration technique.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Self Reported Pain

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Infused analgesicActive Control1 Intervention
Patients will be assigned to receive local anesthetic through continuous infusion by pump.
Group II: Infused salinePlacebo Group1 Intervention
Patients will be assigned to receive saline through continuous infusion by pump.

Find a Location

Who is running the clinical trial?

Ascension HealthLead Sponsor
25 Previous Clinical Trials
2,761 Total Patients Enrolled
Ascension Genesys HospitalLead Sponsor
18 Previous Clinical Trials
1,943 Total Patients Enrolled
Tarik Wasfie, MDPrincipal InvestigatorAscension Health
2 Previous Clinical Trials
261 Total Patients Enrolled

Media Library

Infused analgesic Clinical Trial Eligibility Overview. Trial Name: NCT04173312 — Phase 3
Pain Management Research Study Groups: Infused saline, Infused analgesic
Pain Management Clinical Trial 2023: Infused analgesic Highlights & Side Effects. Trial Name: NCT04173312 — Phase 3
Infused analgesic 2023 Treatment Timeline for Medical Study. Trial Name: NCT04173312 — Phase 3
~28 spots leftby Jun 2025